Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Sci Rep ; 11(1): 11632, 2021 06 02.
Article in English | MEDLINE | ID: mdl-34079038

ABSTRACT

Immunogenicity related to treatment with TNF inhibitors (TNFi) is one of the causes for the decreased attainment of clinical response in patients with rheumatoid arthritis (RA). The B-cell activating factor (BAFF) may be playing a role in the development of immunogenicity. The objective of this study was to analyse the association of baseline concentration of serum B-cell activating factor (BAFF) with immunogenicity after 6 months of TNFi treatment. A total of 127 patients with RA starting a TNFi (infliximab, adalimumab, certolizumab pegol or golimumab) were followed-up for 6 months. Serum samples were obtained at baseline and at 6 months and anti-drug antibody (ADA) and BAFF concentrations were measured. Logistic regression models were employed in order to analyse the association between BAFF concentrations and immunogenicity. Receiver operating characteristic analysis was performed to determine the BAFF concentrations with a greater likelihood of showing immunogenicity association. At 6 months, 31 patients (24%) developed ADA. A significant interaction between the age and baseline BAFF concentration was found for the development of ADA (Wald chi-square value = 5.30; p = 0.02); therefore, subsequent results were stratified according to mean age (≤ / > 55 years). Baseline serum BAFF concentration was independently associated with ADA development only in patients over 55 years (OR = 1.51; 95% CI 1.03-2.21). Baseline serum BAFF ≥ 1034 pg/mL predicted the presence of ADA at 6 months (AUC = 0.81; 95% confidence interval (CI) 0.69-0.93; p = 0.001; positive likelihood ratio = 3.7). In conclusion, our results suggest that the association of BAFF concentration and immunogenicity depends on the patient's age. Baseline serum BAFF concentration predicts the presence of ADA within 6 months of TNFi therapy in older patients with RA.


Subject(s)
Antibodies/blood , Antirheumatic Agents/immunology , Arthritis, Rheumatoid/immunology , B-Cell Activating Factor/immunology , Tumor Necrosis Factor Inhibitors/immunology , Tumor Necrosis Factor-alpha/immunology , Adalimumab/immunology , Adalimumab/therapeutic use , Aged , Antibodies, Monoclonal/immunology , Antibodies, Monoclonal/therapeutic use , Antirheumatic Agents/antagonists & inhibitors , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/diagnosis , Arthritis, Rheumatoid/drug therapy , Arthritis, Rheumatoid/genetics , B-Cell Activating Factor/antagonists & inhibitors , B-Cell Activating Factor/genetics , B-Lymphocytes/drug effects , B-Lymphocytes/immunology , B-Lymphocytes/pathology , Certolizumab Pegol/immunology , Certolizumab Pegol/therapeutic use , Cohort Studies , Gene Expression , Humans , Infliximab/immunology , Infliximab/therapeutic use , Male , Middle Aged , Pilot Projects , Prognosis , Tumor Necrosis Factor Inhibitors/therapeutic use , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Necrosis Factor-alpha/genetics
2.
Dermatol Online J ; 23(11)2017 Nov 15.
Article in English | MEDLINE | ID: mdl-29447631

ABSTRACT

Methotrexate is a mainstay treatment for autoimmune and inflammatory conditions in the field of Dermatology. However, in some patients, its use is associated with significant side effects and toxicity. Folate supplementation with either folic acid or folinic acid often mitigates side effects and reduces the incidence of systemic toxicity related to methotrexate. Although the value of methotrexate is clear, debate remains about folate supplementation. There is little agreement about the proper dosing or frequency of folate supplementation as many believe that daily folate supplementation can reduce methotrexate efficacy. Although daily use of folic acid does not appear to affect methotrexate efficacy, dosing of folinic acid close to methotrexate administration may hinder methotrexate efficacy. Therefore, folic acid should be used daily with methotrexate to ameliorate side effects, whereas folinic acid should only be used for methotrexate toxicity.


Subject(s)
Antirheumatic Agents/antagonists & inhibitors , Folic Acid/therapeutic use , Methotrexate/antagonists & inhibitors , Antirheumatic Agents/pharmacokinetics , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Biological Availability , Dermatologic Agents/antagonists & inhibitors , Dermatologic Agents/pharmacokinetics , Dermatologic Agents/therapeutic use , Drug Antagonism , Humans , Methotrexate/pharmacokinetics , Methotrexate/therapeutic use , Psoriasis/drug therapy
3.
Biomed Res Int ; 2014: 689426, 2014.
Article in English | MEDLINE | ID: mdl-24511542

ABSTRACT

OBJECTIVE: This longitudinal study aims to determine if statins inhibit the response to rituximab in rheumatoid arthritis (RA) patients. METHODS: 41 patients initiating rituximab were included; 17 patients were exposed to the combination of statins and rituximab. The total cholesterol, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) were assessed. The clinical response was evaluated using Disease Activity Score (DAS28) and European League against Rheumatism (EULAR) response at 6 and 18 months. RESULTS: A tendency of increasing in DAS28 was observed in statin-exposed group but the correlation was very weak (at 18 months: r = 0.013, P = 0.952). The statin-exposed status was negatively and very weakly correlated with EULAR response at 6 months (r = -0.073, P = 0.661) and 18 months (r = -0.197, P = 0.244). There was a negative correlation between statin-exposed status and inflammatory markers values (ESR and CRP); however, the correlation was very weak. The use of statin did not influence the cardiovascular risk measured by modified Systematic Coronary Risk Evaluation (mSCORE). CONCLUSIONS: Long-term significant inhibitory effects of statins on rituximab treatment in RA have not been proved using clinical response scores or biologic markers.


Subject(s)
Antibodies, Monoclonal, Murine-Derived/therapeutic use , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Adult , Antirheumatic Agents/antagonists & inhibitors , Arthritis, Rheumatoid/epidemiology , Arthritis, Rheumatoid/physiopathology , Drug Interactions , Female , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Longitudinal Studies , Male , Middle Aged , Prospective Studies , Rituximab , Romania/epidemiology , Treatment Outcome , Young Adult
4.
Arthritis Care Res (Hoboken) ; 65(3): 476-80, 2013 Mar.
Article in English | MEDLINE | ID: mdl-22949223

ABSTRACT

OBJECTIVE: To evaluate the influence of abatacept (ABA) and associated contributing factors on pandemic 2009 influenza A/H1N1 vaccine immunogenicity in rheumatoid arthritis (RA) patients. METHODS: The response to a nonadjuvanted monovalent pandemic 2009 influenza A/H1N1 killed virus vaccine was analyzed in 11 RA patients using ABA (RA-ABA), most with concomitant nonbiologic disease-modifying antirheumatic drugs (DMARDS), and compared to 33 age-matched RA patients on methotrexate (MTX) and 55 healthy controls, all without previous seroprotection. Clinical and laboratory evaluations were performed before and 21 days after vaccination. Anti-influenza antibody titers were measured by hemagglutination inhibition assay. Seroprotection (antibody titers ≥1:40) and the factor increase (FI) in the geometric mean titers (GMTs) were calculated. Prevaccination lymphocyte counts and gammaglobulin levels were determined. RESULTS: Sex distribution, disease duration, and the Disease Activity Score in 28 joints were similar in the RA groups (P > 0.05). After vaccination, seroprotection was significantly reduced in RA-ABA patients compared to RA-MTX patients (9% versus 58%; P = 0.006) and controls (69%; P ≤ 0.001). FI-GMT was severely reduced in RA-ABA patients compared to RA-MTX patients (1.8 [1.4-2.3] versus 8.7 [5.2-17.4]; P < 0.001) and controls (11.5 [8.0-16.7]; P ≤ 0.001). Lymphocyte counts were comparable in RA groups (P > 0.05), but RA-ABA patients had slightly lower gammaglobulin levels than RA-MTX patients (0.9 gm/dl [0.6-1.8] versus 1.2 gm/dl [0.8-1.7]; P = 0.03), although almost all were within the normal range values. CONCLUSION: The current study established that ABA, in association with traditional DMARDs, significantly reduces the humoral response to pandemic 2009 influenza A/H1N1 vaccine in RA patients. The results suggest an influence of costimulatory modulation in humoral response to this vaccine.


Subject(s)
Arthritis, Rheumatoid/immunology , Arthritis, Rheumatoid/therapy , Immunoconjugates/therapeutic use , Immunosuppressive Agents/therapeutic use , Influenza A Virus, H1N1 Subtype/immunology , Influenza Vaccines/antagonists & inhibitors , Influenza Vaccines/therapeutic use , Pandemics , Abatacept , Adult , Aged , Aged, 80 and over , Antirheumatic Agents/antagonists & inhibitors , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/epidemiology , Female , Humans , Immunosuppressive Agents/antagonists & inhibitors , Male , Middle Aged , Pandemics/prevention & control , Prospective Studies
5.
Lab Invest ; 91(5): 719-31, 2011 May.
Article in English | MEDLINE | ID: mdl-21339747

ABSTRACT

Methotrexate (MTX) is widely utilized for the treatment of patients with rheumatoid arthritis (RA); however, recent observation of the MTX-resistant patients proposed some difficulty in MTX-dependent therapeutic approach for RA. To access cellular events related to MTX resistance in RA in respect to inflammatory bone destruction, we investigated on an involvement of the potent inflammatory mediator adenosine in the regulation of osteoclastogenesis and inflammatory bone destruction. In rats with adjuvant-induced arthritis (AA rats), MTX efficiently suppressed bone destruction when it was administrated within 3 days after adjuvant injection, while it could not suppress inflammatory bone destruction if MTX was injected at the time of onset of inflammation (at day 10 after adjuvant injection). Time-course change in the level of plasma adenosine of AA rats was estimated by use of high-performance liquid chromatography and elucidated that adenosine level was markedly elevated till 10 days after adjuvant injection. In vitro bone marrow culture system for evaluating osteoclastogenesis, MTX markedly suppressed osteoclastogenesis in a stromal cell-dependent manner. This MTX-induced suppression of osteoclastogenesis was abrogated by the addition of adenosine. MTX suppressed the expression of mRNA for the receptor activator NF-κB ligand (RANKL), but it did not suppress the expression of osteoprotegerin (OPG). The addition of MTX and adenosine together markedly suppressed the level of OPG expression. Abolishment of MTX action by adenosine was significantly blocked by MRS1754, a highly selective antagonist for the A(2b) adenosine receptor (A(2b)AR), but not by caffeine, an antagonist for A1, A(2a), A3 AR (A1AR, A(2a)AR, and A3AR), which suggests that adenosine acts through A(2b)AR. Immunohistochemical studies showed abundant expression of A(2b)AR in cells localized in the bone-bone marrow boundary of the distal tibia in AA rats but not in control rats. When adenosine was injected in the ankle joints of MTX-treated AA rats, the suppressive effects of MTX on bone destruction was abolished. The current data therefore suggest that upregulation of adenosine production abolished the suppressive effect of MTX on osteoclastic bone destruction. Involvement of the adenosine-A(2b)AR system may explain MTX resistance in RA.


Subject(s)
Adenosine/physiology , Antirheumatic Agents/antagonists & inhibitors , Arthritis, Experimental/drug therapy , Bone and Bones/pathology , Methotrexate/antagonists & inhibitors , Osteoclasts/drug effects , Adenosine/blood , Animals , Antirheumatic Agents/pharmacology , Antirheumatic Agents/therapeutic use , Arthritis, Experimental/pathology , Base Sequence , Chromatography, High Pressure Liquid , DNA Primers , Immunohistochemistry , Methotrexate/pharmacology , Methotrexate/therapeutic use , Osteoclasts/cytology , Osteoprotegerin/genetics , Osteoprotegerin/metabolism , RANK Ligand/genetics , RANK Ligand/metabolism , Rats , Rats, Inbred Lew , Rats, Sprague-Dawley , Reverse Transcriptase Polymerase Chain Reaction
7.
Rheumatology (Oxford) ; 46(1): 146-9, 2007 Jan.
Article in English | MEDLINE | ID: mdl-16782732

ABSTRACT

OBJECTIVES: To observe the course of the disease activity in rheumatoid arthritis (RA) patients treated with the standard infliximab dosing regimen and to adjust treatment guided by the pattern of disease activity. METHODS: All RA patients starting infliximab treatment were included and observed for at least 37 weeks. At infusion 4 (week 14), European League Against Rheumatism response was assessed. In moderate responders the dose was unchanged and the disease activity was carefully observed. In case of stable disease activity, the dose was increased at infusion 5 (week 22). In case of a temporary response the interval was reduced. Paired t-testing was applied to the disease activity score with 28-joint counts (DAS28) at week 22 and study endpoint. RESULTS: A total of 76 patients were included. Response after 14 weeks: good 22 (29%) patients, moderate 26 (34%) patients, and non-response in 21 patients. Seven patients (9%) dropped out before week 14 due to adverse events (5) or patients' initiative (2). In patients with moderate response, the following disease course between infusion 4 and 5 was observed: improvement to good response 6, temporary response 6, stable disease activity 6, drop out 8. In moderate responders, interval reduction and dose increase resulted in a decrease in mean DAS28 from 5.1 to 3.6 [P = 0.005, mean interval 5.6 weeks, mean infliximab dose 4.8 mg/kg/8 week (endpoint)] and from 4.1 to 3.6 [P = 0.04, mean infliximab dose 7.3 mg/kg/8 week (endpoint)], respectively. CONCLUSION: Three different patterns of disease activity were observed in moderate responders after 14 weeks of infliximab treatment, i.e. further improvement, no change in disease activity or a temporary response. Both interval reduction and dose increase significantly reduced disease activity, however, with different mean infliximab dosages. In good responders the response was often sustained over follow-up, whereas non-responders showed modest or no improvement despite dose adjustments.


Subject(s)
Antibodies, Monoclonal/administration & dosage , Antirheumatic Agents/antagonists & inhibitors , Arthritis, Rheumatoid/drug therapy , Adult , Aged , Antibodies, Monoclonal/therapeutic use , Antirheumatic Agents/therapeutic use , Drug Administration Schedule , Drug Monitoring/methods , Female , Humans , Infliximab , Male , Middle Aged , Patient Dropouts , Prospective Studies , Severity of Illness Index , Treatment Failure , Treatment Outcome , Tumor Necrosis Factor-alpha/antagonists & inhibitors
9.
Ann Rheum Dis ; 63(12): 1632-7, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15547088

ABSTRACT

OBJECTIVES: To test whether the active metabolite of leflunomide (LEF-M), in addition to blocking the proliferation of activated lymphocytes by inhibiting dihydro-orotate dehydrogenase (DHODH), influences the transendothelial migration (TEM) of peripheral blood mononuclear cells (PBMC). METHODS: In an in vitro model of PBMC transmigration through an endothelial cell (EC) barrier, PBMC were re-collected in three groups: cells not adherent to the EC, cells bound to, and cells which had migrated through, the EC layer. Experiments in which cells were pretreated with LEF-M (in the absence or in the presence of uridine) were compared with parallel experiments in the presence of medium alone. RESULTS: Preincubation of EC with LEF-M led to a 36 (SEM 16)% reduction in PBMC TEM (p<0.05). Likewise, preincubation of PBMC induced a reduction in their TEM of 39 (9)% (p<0.005). Incubation of both PBMC and EC with LEF-M had an additive effect (mean reduction of 48 (6)%, p<0.005). Incubation of PBMC with LEF-M also decreased monocytic CD44 expression (p<0.005) and PBMC-hyaluronan binding (p<0.05). Incubation of cells with LEF-M and uridine in addition to LEF-M reversed the inhibition of migration, suggesting that the observed effects were due to DHODH inhibition. Fluorocytometric analysis of PBMC subsets within the migrated population showed a decrease of monocytes, but not of B or T cells, after LEF-M treatment. CONCLUSIONS: LEF-M reduces monocytic adhesion molecule expression and TEM and may thus interfere with monocyte and EC activities in RA. Thus, the clinical effects of leflunomide may, at least in part, be due to blocking cell traffic into the inflamed synovia.


Subject(s)
Antirheumatic Agents/pharmacology , Endothelium, Vascular/drug effects , Isoxazoles/pharmacology , Leukocytes, Mononuclear/drug effects , Antirheumatic Agents/antagonists & inhibitors , Cell Adhesion/drug effects , Cell Movement/drug effects , Cells, Cultured , Chemotaxis, Leukocyte/drug effects , Endothelium, Vascular/cytology , Flow Cytometry , Humans , Hyaluronic Acid/metabolism , Isoxazoles/antagonists & inhibitors , Leflunomide , Leukocytes, Mononuclear/physiology , Methotrexate/pharmacology , Uridine/pharmacology
10.
Br J Pharmacol ; 142(4): 749-55, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15159275

ABSTRACT

1. Acute promyelocytic leukaemia (APL) is characterized by a block in differentiation at the promyelocyte stage. Here, we describe the effects of auranofin (AF), a coordinated gold compound, on apoptosis and differentiation of APL cells. 2. Nucleosomal DNA fragmentation assay and Hoechst 33342 staining indicated that AF induced apoptosis in APL-derived NB4 cells at low concentrations (0.5-1.0 microm). The AF-induced apoptosis involved caspase-3 activation and specific cleavage of poly-ADP-ribose polymerase. 3. The AF-treated NB4 cells also produced reactive oxygen species (ROS) and cotreatment with N-acetyl-l-cysteine protected the NB4 cells from AF-induced apoptosis. 4. Expression of the CD11b cell surface marker and C/EBPepsilon was increased when the cells were treated for 4 days with 0.3 microm AF and a physiological concentration of all-trans retinoic acid (ATRA, 5 nm). Treatment with AF in combination with ATRA markedly increased the number of cells with differentiated features, such as lobed or multiple nuclei and numerous granules and vacuoles. At these low concentrations, neither AF nor ATRA alone induced significant cell differentiation. 5. These findings suggest not only that AF induces caspase-3-dependent apoptosis via a mechanism involving ROS, but also that the combined treatment with AF and ATRA induces differentiation of NB4 cells. Our results demonstrate a novel characteristic of AF from which an effective drug treatment of APL might be developed.


Subject(s)
Apoptosis/drug effects , Auranofin/adverse effects , Drug Therapy, Combination , Leukemia, Promyelocytic, Acute/drug therapy , Tretinoin/therapeutic use , Acetylcysteine/pharmacology , Antigens, Surface/drug effects , Antigens, Surface/genetics , Antirheumatic Agents/adverse effects , Antirheumatic Agents/antagonists & inhibitors , Antirheumatic Agents/chemistry , Apoptosis/physiology , Auranofin/antagonists & inhibitors , Auranofin/chemistry , Benzimidazoles , CD11b Antigen/genetics , CD11b Antigen/metabolism , Caspase 3 , Caspases/metabolism , Cell Differentiation/drug effects , DNA/chemistry , DNA/drug effects , Fluorescent Dyes , HL-60 Cells , Humans , Korea , Leukemia, Promyelocytic, Acute/pathology , Leukemia, Promyelocytic, Acute/physiopathology , Nucleosomes/chemistry , Nucleosomes/drug effects , Reactive Oxygen Species/metabolism , Signal Transduction/physiology , Tretinoin/pharmacology , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...